Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes
Sponsor: Maastricht University Medical Center
Summary
Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions. Methylglyoxal is a by-product of glycolysis and forms advanced glycation endproducts (AGEs) on proteins and DNA, thereby disrupting their function. Preventing methylglyoxal accumulation and AGEs formation may offer a therapeutic option for treating microvascular complications in diabetics. Pyridoxamine is a vitamin B6 vitamer that scavenges methylglyoxal and thereby inhibits the formation of AGEs. In this study, the researchers investigate whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation.
Official title: The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes: a Double-blind Randomized Placebo-controlled Crossover Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-03-21
Completion Date
2026-12-31
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
Pyridoxamine 300mg per day
oral supplement
Placebo 300mg placebo per day
oral supplement
Locations (1)
Academic Hospital Maastricht
Maastricht, Netherlands